Well-suited for pre-surgical planning and post-surgical follow-up of liver lesions
- See increased contrast between normal and abnormal liver tissue
- See smaller lesions (0.5 cm - 1.0 cm)
- See new lesions
In 1996, FERIDEX I.V.® (ferumoxides injectable solution) was introduced as the world's first organ-specific MR imaging agent. Since then it has been used to detect and evaluate liver lesions associated with an alteration in the reticuloendothelial system (RES). As a superparamagnetic iron oxide (SPIO), FERIDEX I.V. is taken up by RES cells in the liver while tissues with decreased RES function retain their signal intensity. Because of this mechanism of action, FERIDEX I.V. is considered a "negative" contrast agent (i.e., the liver decreases in signal intensity, not the lesion).
FERIDEX I.V.® (ferumoxides injectable solution): Anaphylactic-like reactions and hypotension have been noted in some patients receiving FERIDEX I.V., other iron and dextran containing formulations, or radiographic contrast media. In clinical trials, anaphylactic and allergic adverse events occurred in 11/2240 (.05%) of the patients who received FERIDEX I.V. These events included dyspnea, other respiratory symptoms, angioedema, generalized urticaria, and hypotension;and required treatment.
FERIDEX I.V.® (ferumoxides injectable solution) is a registered trademark of Advanced Magnetic Industries, Inc.
|
